hsa-miR-574-5p Decreases Expression of Prostate Cancer Therapy Resistance Driver ARV7

Prostate cancer has high incidence worldwide and the development of novel therapies are urgently needed. Currently used androgen receptor signaling inhibitors (ARSI) targeting the full-length androgen receptor (ARFL) are initially effective, however most patients develop therapy resistance denominated as castration-resistant prostate cancer (CRPC). On the molecular level, the constitutively active AR splice variant ARV7 promotes CRPC progression and cannot be targeted by ARSI due to an absent ligand binding domain. However, due to its distinct 3' untranslated region (3′UTR) compared to ARFL, ARV7 may be differentially regulated by microRNAs (miRNAs), which could be used as therapeutic opportunity. Of note, single nucleotide polymorphisms (SNPs) within this region could influence miRNA binding. Using an in silico screening approach, we identified SNPs predicted to alter miRNA binding sites in the ARV7 3′UTR. Selected miRNAs were functionally evaluated in CRPC cells for their effects on ARV7 and ARFL expression, allele-specific binding, and cell proliferation. Among the candidates with predicted allele-specific ARV7 binding, hsa-miR-574-5p was selected for further analyses after confirmation of allele-specific effects in luciferase assays. Overexpression of hsa-miR-574-5p in the ARV7-expressing cell line 22Rv1 was able to reduce ARV7 mRNA and protein levels without affecting ARFL. Functionality of this miRNA was demonstrated by reduced proliferation of 22Rv1 upon induced expression of hsa-miR-574-5p. In conclusion, we identified hsa-miR-574-5p as a miRNA binding to the 3'UTR of ARV7. This finding may be useful for the development of therapies specifically targeting ARV7 driving CRPC.

Authors

Institutions

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1807.v1
Primary Topic
Prostate Cancer Treatment and Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

hsa-miR-574-5p Decreases Expression of Prostate Cancer Therapy Resistance Driver ARV7

Frank Claessens, Frederic Romain Santer, Miroslav Peřina, Jasper Van Goubergen et al.
Preprints.org
Prostate Cancer Treatment and Research
preprint

hsa-miR-574-5p Decreases Expression of Prostate Cancer Therapy Resistance Driver ARV7

Frank Claessens, Frederic Romain Santer, Miroslav Peřina, Jasper Van Goubergen, Marcus Victor Cronauer, Elisa Morales, Marcus Cronauer, Samira Walder, Frank Claessens, Miroslav Perina, Jasper Van Goubergen, Frédéric Santer
preprint en

Abstract

Prostate cancer has high incidence worldwide and the development of novel therapies are urgently needed. Currently used androgen receptor signaling inhibitors (ARSI) targeting the full-length androgen receptor (ARFL) are initially effective, however most patients develop therapy resistance denominated as castration-resistant prostate cancer (CRPC). On the molecular level, the constitutively active AR splice variant ARV7 promotes CRPC progression and cannot be targeted by ARSI due to an absent ligand binding domain. However, due to its distinct 3' untranslated region (3′UTR) compared to ARFL, ARV7 may be differentially regulated by microRNAs (miRNAs), which could be used as therapeutic opportunity. Of note, single nucleotide polymorphisms (SNPs) within this region could influence miRNA binding. Using an in silico screening approach, we identified SNPs predicted to alter miRNA binding sites in the ARV7 3′UTR. Selected miRNAs were functionally evaluated in CRPC cells for their effects on ARV7 and ARFL expression, allele-specific binding, and cell proliferation. Among the candidates with predicted allele-specific ARV7 binding, hsa-miR-574-5p was selected for further analyses after confirmation of allele-specific effects in luciferase assays. Overexpression of hsa-miR-574-5p in the ARV7-expressing cell line 22Rv1 was able to reduce ARV7 mRNA and protein levels without affecting ARFL. Functionality of this miRNA was demonstrated by reduced proliferation of 22Rv1 upon induced expression of hsa-miR-574-5p. In conclusion, we identified hsa-miR-574-5p as a miRNA binding to the 3'UTR of ARV7. This finding may be useful for the development of therapies specifically targeting ARV7 driving CRPC.

Preprints.org
University of Bonn (DE), Innsbruck Medical University (AT), Technische Universität Darmstadt (DE), Palacký University Olomouc (CZ), KU Leuven (BE)
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon